AU · rank #20 · 2026-09-08
IMCD
AMSTERDAM · EUR · $6.66B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.716 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.09 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 8 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $117.36 | +21.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +8.42% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +25.0% |
| 52w high | $103.20 |
| Market cap (USD) | $6.66B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
IMCD NV is a leading global distributor and formulator of specialty chemicals and food ingredients, serving diverse industrial and life-science end markets through a scale-driven global network.
Rationale
The 21.3% analyst upside and 90% revision agreement are strongly validated by IMCD's robust Q2 2026 organic growth recovery and solid cash EPS generation, which have driven consistent upward earnings revisions over the last 30, 60, and 90 days.
Material risks
- 1Margin dilution and integration friction from structurally lower-margin acquisitions like Dong Yang FT and Willows Ingredients, which have already contributed to a 0.7 percentage point year-over-year decline in H1 2026 gross margins.
- 2Vulnerability to cyclical demand softness and regional industrial slowdowns, particularly in Europe, which could disrupt the newly recovered organic gross profit and EBITA momentum.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.